bioMerieux : Feedback from the analysts’ meeting: growth levers exercised correctly
>Positive tone on organic performance and new launches - Key takeaways:SpotFire (key launch of 2024): confidence displayed on achieving the full-year sales target of € 80m (€ 33m in H1). The distribution deal with McKesson should deliver more in H2 and Q2 is always the weakest quarter (due to its sensitivity to the respiratory season). In July and August, the pace of installation was deemed “good” by the CEO: Q3 and Q4 could create upside. Compared to Q4 2023 whi...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.